EHA 2024

To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to myelofibrosis and polycythemia vera here.

CONGRESS | #EHA2024 | Claire Harrison @harrisoncn1 shares data from the phase II RESTORE trial of elritercept for the treatment of myelofibrosis and to mitigate ruxolitinib-associated cytopenias; concluding that elritercept was generally well tolerated with a RP2D selected of… pic.twitter.com/HPiO8MQsit

— MPN_Hub (@MPN_Hub) June 15, 2024

CONGRESS | #EHA2024 | @doctorpemm @MDAndersonNews presents efficacy and safety data from the phase III TRANSFORM-1 study of navitoclax plus ruxolitinib in previously untreated #myelofibrosis. In the nav+rux arm SVR35 was 63.2% vs 31.5% in the placebo+rux arm, TSS -9.7 vs -11.1,… pic.twitter.com/yoiQsjBjKs

— MPN_Hub (@MPN_Hub) June 15, 2024

CONGRESS | #EHA2024 | @RaajitRampal @MSKCancerCenter discusses the latest data from the phase III MANIFEST-2 trial of pelabresib with ruxolitinib for JAKi-naive #myelofibrosis. SVR35 65.9% vs 35.2% in RUX+placebo arm, loss of SVR35 13.4% vs 27.8%, dual SVR35/TSS50 40.2% vs 18.5%.… pic.twitter.com/FgjU1y9Suv

— MPN_Hub (@MPN_Hub) June 15, 2024

CONGRESS | #EHA2024 | @RaajitRampal @MSKCancerCenter shares preliminary evidence of bone marrow recovery from the MANIFEST-2 study of combination pelabresib-ruxolitinib JAK2 inhibitor-naïve #myelofibrosis. Pharmacodynamic markers indicate the potential for the combination to… pic.twitter.com/o4aEH85W4J

— MPN_Hub (@MPN_Hub) June 15, 2024

CONGRESS | POSTER | #ASCO24 | @DrJoeScandura presents the rationale, trial design, primary endpoints, and eligibility criteria for the phase II SENTRY-2 (XPORT-MF-044) clinical trial of selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia;… pic.twitter.com/OW8qLIGX3G

— MPN_Hub (@MPN_Hub) June 5, 2024

CONGRESS | POSTER | #ASCO24 | @sankalparoramd @MDAndersonNews shares the long term follow-up results of ruxolitinib in combination with azacitidine for the treatment of #myelofibrosis. An ORR rate of 74% was observed, median OS was 46 months, the most common higher grade AEs were… pic.twitter.com/6eEDCxx979

— MPN_Hub (@MPN_Hub) June 5, 2024

CONGRESS | POSTER | #ASCO24 | Ruben Mesa @mpdrc @WakeCancer shares the long-term survival, adjusted for treatment crossover, in pts with MF treated with momelotinib vs danazol from the MOMENTUM trial; concluding that long-term OS and LFS was observed in both arms, highlighting… pic.twitter.com/rKiLWZKLOh

— MPN_Hub (@MPN_Hub) June 4, 2024

CONGRESS | #ASCO24 | @RaajitRampal @MSKCancerCenter shares the updated safety and efficacy data from MANIFEST-2 of pelabresib + rux vs placebo + rux for JAKi-naïve myelofibrosis.
Loss of SVR35 13.4% vs 27.8%, SAEs 29.7% vs 29.4%, Grade ≥3 AE 49.1% vs 57%, anemia 44.8% vs 55.1%,… pic.twitter.com/CmMPOsxp9v

— MPN_Hub (@MPN_Hub) June 4, 2024

CONGRESS | #EHA2024 | @jjkiladjian @HopSaintLouis discusses the correlation between JAK2V617F molecular response and EFS in early #polycythemiavera. A 10% lower JAK2V617F allele burden was associated with a 34% decrease risk of events. Data also support the use of ropeginterferon… pic.twitter.com/TeWLaHfml7

— MPN_Hub (@MPN_Hub) June 15, 2024